Increased cardiac distribution of mono-PEGylated Radix Ophiopogonis polysaccharide in both myocardial infarction and ischemia/reperfusion rats

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 409-418

  Yao, ChunXia ^a   Shi, XiaoLi ^a   Lin, Xiao ^a   Shen, Lan ^a   Xu, DeSheng ^b   Feng, Yi ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SHUGUANG HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Heart distribution; Myocardial ischemia; Polyethylene glycol; Radix Ophiopogonis polysaccharide

Indexed keywords

ISOPRENALINE; MACROGOL; OPHIOPOGON ROOT; POLYSACCHARIDE; HERBACEOUS AGENT; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONJUGATION; CONTROLLED STUDY; CORONARY ARTERY LIGATION; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE; HYDRODYNAMICS; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MACROMOLECULE; MALE; MOLECULAR SIZE; NONHUMAN; PERMEABILITY; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RAT; REPERFUSION INJURY; SENSITIVITY AND SPECIFICITY; STANDARD; ANIMAL; CARDIAC MUSCLE; CHEMISTRY; METABOLISM; PLANT ROOT;

ANIMALIA; RATTUS;

ANIMALS; DRUGS, CHINESE HERBAL; MYOCARDIAL INFARCTION; MYOCARDIUM; OPHIOPOGON; PLANT ROOTS; POLYETHYLENE GLYCOLS; POLYSACCHARIDES; RATS; REPERFUSION INJURY;

EID: 84921267384     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S73462     Document Type: Article

References (44)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart Disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation. 2014;129:e28-e292.
2. Takahama H, Minamino T, Asanuma H, et al. Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats. J Am Coll Cardiol. 2009;53(8):709-717.
3. Verma DD, Hartner WC, Levchenko TS, Bernstein EA, Torchilin VP. ATP-loaded liposomes effectively protect the myocardium in rabbits with an acute experimental myocardial infarction. Pharm Res. 2005;22(12):2115-2120.
4. Verma DD, Hartner WC, Thakkar V, Levchenko TS, Torchilin VP. Protective effect of coenzyme Q10-loaded liposomes on the myocardium in rabbits with an acute experimental myocardial infarction. Pharm Res. 2007;24(11):2131-2137.
5. Scott RC, Rosano JM, Ivanov Z, et al. Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J. 2009;23(10):3361-3367.
6. Mueller TM, Marcus ML, Mayer HE, Williams JK, Hermsmeyer K. Liposome concentration in canine ischemic myocardium and depolarized myocardial cells. Circ Res. 1981;49(2):405-415.
7. Rodriguez M, Cai WJ, Kostin S, Lucchesi BR, Schaper J. Ischemia depletes dystrophin and inhibits protein synthesis in the canine heart: mechanism of myocardial ischemic injury. J Mol Cell Cardiol. 2005;38(5):723-733.
8. Lukyanov AN, Hartner WC, Torchilin VP. Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits. J Control Release. 2004;94(1):187-193.
9. Sun GL, Lin X. [Mechanisms and strategies for targeting drugs to myocardial ischemic regions]. Yao Xue Xue Bao. 2010;45(7):827-832. Chinese.
10. Torchilin VP. Targeting of drugs and drug carriers within the cardiovascular system. Adv Drug Deliv Rev. 1995;17:75-101.
11. Scott RC, Crabbe D, Krynska B, Ansari R, Kiani MF. Aiming for the heart: targeted delivery of drugs to diseased cardiac tissue. Expert Opin Drug Deliv. 2008;5(4):459-470.
12. Pasut G, Veronese FM. Polymer-drug conjugation, recent achievements and general strategies. Prog Polym Sci. 2007;32(8-9):933-961.
13. Pasut G, Veronese FM. State of the art in PEGylation: the great versatility achieved after forty years of research. J Control Release. 2012;161(2):461-472.
14. Kang JS, DeLuca PP, Lee KC. Emerging PEGyated drugs. Expert Opin Emerg Drugs. 2009;14(2):363-380.
15. Wang S, Zhang Z, Lin X, Xu DS, Feng Y, Ding K. A polysaccharide, MDG-1, induces S1P1 and bFGF expression and augments survival and angiogenesis in the ischemic heart. Glycobiology. 2010;20(4):473-484.
16. Zheng Q, Feng Y, Xu DS, Lin X, Chen YZ. Influence of sulfation on anti-myocardial ischemic activity of Ophiopogon japonicus polysaccharide. J Asian Nat Prod Res. 2009;11(4):306-321.
17. Lin X, Wang Z, Sun G, Shen L, Xu D, Feng Y. A sensitive and specific HPGPC-FD method for the study of pharmacokinetics and tissue distribution of Radix Ophiopogonis polysaccharide in rats. Biomed Chromatogr. 2010;24(8):820-825.
18. Lin X, Xu DS, Feng Y, Shen L. Determination of Ophiopogon japonicus polysaccharide in plasma by HPLC with modified postcolumn fluorescence derivatization. Anal Biochem. 2005;342(2):179-185.
19. Sun G, Lin X, Shen L, et al. Mono-PEGylated radix ophiopogonis polysaccharide for the treatment of myocardial ischemia. Eur J Pharm Sci. 2013;49(4):629-636.
20. Lin X, Wang ZJ, Wang S, et al. Comparison of tissue distribution of a PEGylated Radix Ophiopogonis polysaccharide in mice with normal and ischemic myocardium. Eur J Pharm Biopharm. 2011;79(3):621-626.
21. Lin X, Wang ZJ, Huang F, et al. Long-circulating delivery of bioactive polysaccharide from radix ophiopogonis by PEGylation. Int J Nanomedicine. 2011;6:2865-2872.
22. Xu DS, Feng Y, Lin X, Deng HL, Fang JN, Dong Q. [Isolation, purification and structural analysis of a polysaccharide MDG-1 from Ophiopogon japonicas]. Yao Xue Xue Bao. 2005;40(7):636-639. Chinese.
23. Lin X, Wang S, Jiang Y, et al. Poly(ethylene glycol)-Radix Ophiopogonis polysaccharide conjugates: preparation, characterization, pharmacokinetics and in vitro bioactivity. Eur J Pharm Biopharm. 2010;76(2):230-237.
24. Ye J, Yang L, Sethi R, et al. A new technique of coronary artery ligation: experimental myocardial infarction in rats in vivo with reduced mortality. Mol Cell Biochem. 1997;176(1-2):227-233.
25. Wang ZJ, Lin X, Shen L, Feng Y, Xu DS, Ruan KF. [Pharmacokinetics of a long-circulating PEGylated Radix Ophiopogonis polysaccharide]. Yao Xue Xue Bao. 2011;46(10):1257-1261. Chinese.
26. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63(3):131-135.
27. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136-151.
28. Torchilin VP. Drug targeting. Eur J Pharm Sci. 2000;11 Suppl 2:S81-S91.
29. Paulis LE, Geelen T, Kuhlmann MT, et al. Distribution of lipid-based nanoparticles to infarcted myocardium with potential application for MRI-monitored drug delivery. J Control Release. 2012;162(2):276-285.
30. Scott RC, Wang B, Nallamothu R, et al. Targeted delivery of antibody conjugated liposomal drug carriers to rat myocardial infarction. Biotechnol Bioeng. 2007;96(4):795-802.
31. Horwitz LD, Kaufman D, Keller MW, Kong Y. Time course of coronary endothelial healing after injury due to ischemia and reperfusion. Circulation. 1994;90(5):2439-2447.
32. Oerlemans MI, Koudstaal S, Chamuleau SA, de Kleijn DP, Doevendans PA, Sluijter JP. Targeting cell death in the reperfused heart: pharmacological approaches for cardioprotection. Int J Cardiol. 2013;165(3):410-422.
33. Fishbein MC, Maclean D, Maroko PR. Experimental myocardial infarction in the rat: qualitative and quantitative changes during pathologic evolution. Am J Pathol. 1978;90(1):57-70.
34. Sun G, Lin X, Hong Y, Feng Y, Ruan K, Xu D. PEGylation for drug delivery to ischemic myocardium: Pharmacokinetics and cardiac distribution of poly(ethylene glycol)s in mice with normal and ischemic myocardium. Eur J Pharm Sci. 2012;46(5):545-552.
35. Feary DJ, Mama KR, Wagner AE, Thomasy S. Influence of general anesthesia on pharmacokinetics of intravenous lidocaine infusion in horses. Am J Vet Res. 2005;66(4):574-580.
36. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013;123(1):92-100.
37. Ware JA, Simons M. Angiogenesis in ischemic heart disease. Nat Med. 1997;3(2):158-164.
38. Dvir T, Bauer M, Schroeder A, et al. Nanoparticles targeting the infarcted heart. Nano Lett. 2011;11(10):4411-4414.
39. Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci. 1994;83(4):601-606.
40. Greenwald RB, Gilbert CW, Pendri A, Conover CD, Xia J, Martinez A. Drug delivery systems: water soluble taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J Med Chem. 1996;39(2):424-431.
41. Venturoli D, Rippe B. Ficoll and dextran vs globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. Am J Physiol Renal Physiol. 2005;288(4):F605-F613.
42. Harrington KJ, Rowlinson-Busza G, Syrigos KN, et al. Pegylated liposome encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clin Cancer Res. 2000;6(12):4939-4949.
43. Harrington KJ, Mohammadtaghi S, Uster PS, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res. 2001;7(2):243-254.
44. Liu Z, Liu LL, Yang TT. Comparative study of myocardial infarction models in two kinds of rat. Prog in Vet Med. 2010;31(4):19-25.